A Phase I Study to Determine the Pharmacokinetics of Buspirone from a Metered Dose Transdermal System (MDTS) in anxiety

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000525684

Enrollment

Registered

2005-09-26

Start date

2002-10-24

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Buspirone Metered Dose Transdermal System (MDTS) and BuSpar up to 5 days.

Study design

Allocation

Non-randomised trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Yes

Inclusion criteria

Healthy volunteers

Exclusion criteria

No exclusion criteria

Outcome results